Brief: Hansa Biopharma Enters $30 Million Convertible Loan Agreement With Athyrium
20/03/2026 07:04
March 20 (Reuters) - Hansa Biopharma AB HNSA.ST: ENTERS $30 MILLION CONVERTIBLE LOAN AGREEMENT WITH ATHYRIUM Source text: ID:nWkr1qkt4M Further company coverage: HNSA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS